Adenosines, endogenous purine nucleosides, appear in the extracellular space under metabolically stressful conditions associated with ischemia, inflammation, and cell damage. Their activity on innate immunity is prevalently inhibitory and can develop both in infectious and neoplastic diseases. During cancer development, tumor cells that release high concentrations of adenosines can impair the function of tumor-infiltrating lymphocytes and assist tumor growth by neo-angiogenesis. We evaluated the influence of A(2) adenosine receptor (A(2)AR) agonist on cytotoxic-cell response comparing human with other mammalian species (rodents, pigs, goats), both in healthy and in cancer conditions. The A(2)AR agonist developed dose-dependent inhibition of the cytotoxic activity of immune effector cells in all studied species. However, variability of the response was observed in relation to the species and the target cells that were used. Altogether, our data indicate that the A(2)AR plays a central role in adenosine-mediated inhibition of immune response to tumors.

Department of Immunology and Gnotobiology Institute of Microbiology v v i Academy of Sciences of the Czech Republic Prague Czech Republic

Zobrazit více v PubMed

Int J Oncol. 2008 Mar;32(3):527-35 PubMed

Lung Cancer. 2005 Feb;47(2):215-23 PubMed

Folia Microbiol (Praha). 2003;48(3):403-7 PubMed

J Appl Physiol (1985). 1994 Jan;76(1):5-13 PubMed

Biochem J. 2005 Nov 1;391(Pt 3):575-80 PubMed

Cell Signal. 2002 Feb;14(2):99-108 PubMed

Nature. 2001 Dec 20-27;414(6866):916-20 PubMed

Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7 PubMed

Immunol Res. 2006;36(1-3):91-9 PubMed

J Environ Pathol Toxicol Oncol. 1994;13(1):59-61 PubMed

Annu Rev Immunol. 2004;22:657-82 PubMed

Neuropharmacology. 1997 Sep;36(9):1127-39 PubMed

Nat Rev Drug Discov. 2008 Sep;7(9):759-70 PubMed

Melanoma Res. 2003 Dec;13(6):543-8 PubMed

J Neuroimmunol. 2002 Sep;130(1-2):55-65 PubMed

Pharmacol Rev. 2001 Dec;53(4):527-52 PubMed

Biochem Pharmacol. 2003 Feb 15;65(4):493-501 PubMed

Cancer Res. 1990 Jul 15;50(14):4328-31 PubMed

Cell Immunol. 1994 Nov;159(1):85-93 PubMed

J Immunol. 2005 Oct 1;175(7):4383-91 PubMed

Cancer Res. 2006 Aug 1;66(15):7758-65 PubMed

The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques

Antitumor activity of N-acetyl-D-glucosamine-substituted glycoconjugates and combined therapy with keyhole limpet hemocyanin in B16F10 mouse melanoma model